Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus
- PMID: 27920180
- PMCID: PMC5137244
- DOI: 10.1093/infdis/jiw352
Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus
Abstract
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
Keywords: alphavirus; chikungunya virus; vaccine; virus-like particle vaccine; whole-inactivated vaccine.
Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
References
-
- Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 2015; 372:1231–9. - PubMed
-
- Harrison VR, Binn LN, Randall R. Comparative immunogenicities of chikungunya vaccines prepared in avian and mammalian tissues. Am J Trop Med Hyg 1967; 16:786–91. - PubMed
-
- Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. J Immunol 1971; 107:643–7. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical